Skip to content
10-Q

Quarterly Report

Reviva Pharmaceuticals Holdings, Inc. RVPH

0001437749-25-034827

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 11, 2025 115.06M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$18.8M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$24.44M
Short Term Debt Q3 2025 · Sep 30, 2025 $0
Short Term Debt Q3 2025 · Dec 31, 2024 $458.15K
Cash And Equivalents Q3 2025 · Sep 30, 2025 $13.18M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $13.48M
Stockholders Equity Q3 2025 · Sep 30, 2025 $4.55M
Stockholders Equity Q3 2025 · Jun 30, 2025 −$459.15K
Stockholders Equity Q3 2025 · Dec 31, 2024 $812.57K
Stockholders Equity Q3 2025 · Sep 30, 2024 −$9.98M
Stockholders Equity Q3 2025 · Jun 30, 2024 −$6.04M
Stockholders Equity Q3 2025 · Dec 31, 2023 $5.72M
Current Liabilities Q3 2025 · Sep 30, 2025 $9.74M
Current Liabilities Q3 2025 · Dec 31, 2024 $14.6M
Total Liabilities Q3 2025 · Sep 30, 2025 $9.78M
Total Liabilities Q3 2025 · Dec 31, 2024 $14.69M
Current Assets Q3 2025 · Sep 30, 2025 $13.51M
Current Assets Q3 2025 · Dec 31, 2024 $14.68M
Total Assets Q3 2025 · Sep 30, 2025 $14.33M
Total Assets Q3 2025 · Dec 31, 2024 $15.5M
Eps Basic Q3 2025 · Sep 30, 2025 −$0.06
Eps Basic Q3 2025 · Sep 30, 2025 −$0.29
Eps Basic Q3 2025 · Sep 30, 2024 −$0.25
Eps Basic Q3 2025 · Sep 30, 2024 −$0.75
Sga Expense Q3 2025 · Sep 30, 2025 $1.9M
Sga Expense Q3 2025 · Sep 30, 2025 $6.67M
Sga Expense Q3 2025 · Sep 30, 2024 $1.6M
Sga Expense Q3 2025 · Sep 30, 2024 $6.29M
Rd Expense Q3 2025 · Sep 30, 2025 $2.13M
Rd Expense Q3 2025 · Sep 30, 2025 $9.97M
Rd Expense Q3 2025 · Sep 30, 2024 $6.86M
Rd Expense Q3 2025 · Sep 30, 2024 $18.23M
Net Income Q3 2025 · Sep 30, 2025 −$4.01M
Net Income Q3 2025 · Sep 30, 2025 −$16.5M
Net Income Q3 2025 · Sep 30, 2024 −$8.37M
Net Income Q3 2025 · Sep 30, 2024 −$23.66M
Operating Income Q3 2025 · Sep 30, 2025 −$4.03M
Operating Income Q3 2025 · Sep 30, 2025 −$16.64M
Operating Income Q3 2025 · Sep 30, 2024 −$8.46M
Operating Income Q3 2025 · Sep 30, 2024 −$24.51M